User login
Key clinical point: Treatment with abaloparatide is associated with a transient increase in heart rate (HR) and a small decrease in post-dose blood pressure (BP) in postmenopausal women with osteoporosis.
Major finding: Abaloparatide showed a significantly higher mean HR change from pretreatment to 1 hour posttreatment on day 1 vs. placebo (mean [standard deviation]: 7.9 [8.5] vs. 1.2 [7.1] beats per minute; P less than .0001). Abaloparatide showed a significantly higher change in systolic and diastolic blood pressure from pre-dose to 1 hour post-dose vs. placebo (−2.7/−3.6 vs. −1.5/−2.3 mmHg; P less than .05). These changes were not associated with an increased risk of serious cardiac adverse events, major adverse cardiovascular events, and heart failure.
Study details: The findings are based on a post-hoc analysis from the ACTIVE and ACTIVExtend trials including 2,460 postmenopausal women with osteoporosis.
Disclosures: Dr. Felicia Cosman, Dr. Steven R Cummings, Dr. Linda R Peterson, and Dr. Dwight A Towler consulted for/received research grants from pharmaceutical companies/research institutes including Amgen; Radius Health, Inc.; and the National Institutes of Health. Dr. Bruce Mitlak and Dr. Yamei Wang are employees of and hold equity in Radius Health, Inc.
Source: Cosman F et al. J Clin Endocrinol Metab. 2020 Jul 13. doi: 10.1210/clinem/dgaa450.
Key clinical point: Treatment with abaloparatide is associated with a transient increase in heart rate (HR) and a small decrease in post-dose blood pressure (BP) in postmenopausal women with osteoporosis.
Major finding: Abaloparatide showed a significantly higher mean HR change from pretreatment to 1 hour posttreatment on day 1 vs. placebo (mean [standard deviation]: 7.9 [8.5] vs. 1.2 [7.1] beats per minute; P less than .0001). Abaloparatide showed a significantly higher change in systolic and diastolic blood pressure from pre-dose to 1 hour post-dose vs. placebo (−2.7/−3.6 vs. −1.5/−2.3 mmHg; P less than .05). These changes were not associated with an increased risk of serious cardiac adverse events, major adverse cardiovascular events, and heart failure.
Study details: The findings are based on a post-hoc analysis from the ACTIVE and ACTIVExtend trials including 2,460 postmenopausal women with osteoporosis.
Disclosures: Dr. Felicia Cosman, Dr. Steven R Cummings, Dr. Linda R Peterson, and Dr. Dwight A Towler consulted for/received research grants from pharmaceutical companies/research institutes including Amgen; Radius Health, Inc.; and the National Institutes of Health. Dr. Bruce Mitlak and Dr. Yamei Wang are employees of and hold equity in Radius Health, Inc.
Source: Cosman F et al. J Clin Endocrinol Metab. 2020 Jul 13. doi: 10.1210/clinem/dgaa450.
Key clinical point: Treatment with abaloparatide is associated with a transient increase in heart rate (HR) and a small decrease in post-dose blood pressure (BP) in postmenopausal women with osteoporosis.
Major finding: Abaloparatide showed a significantly higher mean HR change from pretreatment to 1 hour posttreatment on day 1 vs. placebo (mean [standard deviation]: 7.9 [8.5] vs. 1.2 [7.1] beats per minute; P less than .0001). Abaloparatide showed a significantly higher change in systolic and diastolic blood pressure from pre-dose to 1 hour post-dose vs. placebo (−2.7/−3.6 vs. −1.5/−2.3 mmHg; P less than .05). These changes were not associated with an increased risk of serious cardiac adverse events, major adverse cardiovascular events, and heart failure.
Study details: The findings are based on a post-hoc analysis from the ACTIVE and ACTIVExtend trials including 2,460 postmenopausal women with osteoporosis.
Disclosures: Dr. Felicia Cosman, Dr. Steven R Cummings, Dr. Linda R Peterson, and Dr. Dwight A Towler consulted for/received research grants from pharmaceutical companies/research institutes including Amgen; Radius Health, Inc.; and the National Institutes of Health. Dr. Bruce Mitlak and Dr. Yamei Wang are employees of and hold equity in Radius Health, Inc.
Source: Cosman F et al. J Clin Endocrinol Metab. 2020 Jul 13. doi: 10.1210/clinem/dgaa450.